Media Mentions
2009
Eric Hargen discussed for FDA Week (December 25) provisions in the final Senate version of the health care reform bill that impose limits and hurdles on the Centers for Medicare and Medicaid Services (CMS) for using comparative effectiveness research (CER) to make reimbursement and coverage decisions. The new provisions “did nothing to disturb the underlying other provisions that guide CMS in using this data,” Mr. Hargen observed. He added that under the provisions “CMS has been given a framework in which to use [CER]. They’ve been given an implicit license to use it as long as they use it in a particular way.”
, Health
